In today’s briefing:
- Bio FD&C IPO Preview
- Simcere Pharmaceutical (2096 HK): Focus Shifts to Innovative Drug; COVID-19 Oral Drug in Development
- Genscript Biotech (1548.HK) – The Strength and the Concerns
Bio FD&C IPO Preview
- Bio FD&C is getting ready to complete its IPO in the Korean stock market in February 2022.
- Founded in 2005, Bio FD&C is a company that develops anti-aging materials with plant cell line design and plant cell culture technology.
- Currently, Bio FD&C hasa gray market price of 90,000 won, which is 210% higher than the high end of the IPO price range.
Simcere Pharmaceutical (2096 HK): Focus Shifts to Innovative Drug; COVID-19 Oral Drug in Development
- Simcere Pharmaceutical Group (2096 HK) is transitioning to an innovation and R&D-driven pharmaceutical company, with revenue from innovative pharmaceuticals making greater contribution and R&D pipeline of innovative pharmaceuticals advancing rapidly.
- During H1 2021, Simcere newly added 5 pivotal registrational trials and phase III clinical trials and 1 phase I clinical trial, and received 7 clinical trial approvals.
- Simcere entered into three international partnerships to develop and market innovative drugs in China. The company has also in-licensed an oral COVID-19 drug candidate, which is in pre-clinical stage.
Genscript Biotech (1548.HK) – The Strength and the Concerns
- China attaches great importance to gene therapy and related products, which would be a leader of the third industrial revolution in biomedicine and have broad prospects for future development.
- With obvious strength in this field,Genscript Biotech (1548 HK)’s businesses are in line with the future trend and the outlook is also quite promising, indicating exponential growth potential in valuation.
- However, the potential risks on deterioration of international relations and the concerns on CAR-T commercialization should not be neglected by investors.
Before it’s here, it’s on Smartkarma
